Why the new Theranos film is not a documentary
Tyler Shultz’s reaction to Nathan Fielder’s You Can See Everything is blunt: the film may be funny, thrilling, fascinating, and beautiful, but it is not a documentary. Pretending otherwise, he argues, is dangerous. In the Theranos story, dangerous is not a metaphor. It is the central clinical and ethical problem.
Holmes built a public persona around a promise of blood testing that appeared to compress complexity into convenience. The appeal was easy to understand. Faster testing, less blood, and a system that sounded sleek enough to fit the mythology of Silicon Valley. Yet the collapse of that story exposed something far more serious than corporate embarrassment. It revealed how quickly rhetoric can outrun verification when medicine is marketed like software.
Shultz’s vantage point matters because he was a whistleblower inside the Theranos orbit. His objection in this context is not merely about artistic license. It is about what happens when a film, a scandal, and a highly recognizable fraud start to blur into one another. Once that happens, the public can lose sight of the original harm: patients and clinicians were asked to trust a diagnostic promise before that promise had earned trust.
The danger sits in the gap between spectacle and evidence.
Holmes, performance, and the persistence of a false narrative
The continued fascination with Elizabeth Holmes has always rested on contradiction. She was presented as a visionary while the company she led became synonymous with deception. That contradiction remains powerful on screen because fraud often is cinematic. It has drama, secrecy, confidence, and a cast of characters who believe they are participating in something larger than themselves. But art does not turn a falsehood into a fact.
Shultz’s warning reaches beyond one movie review. When a story about Theranos is treated casually, the original medical failure can be softened into a personality dispute or a Silicon Valley cautionary tale. That flattening does a disservice to the people who rely on laboratory medicine to be boring, accurate, and reproducible. Diagnostics are not supposed to be inspirational. They are supposed to be trustworthy.
Elizabeth Holmes’s continuing presence in public culture shows how durable a well-told lie can be. In a different setting, that durability might only distort reputation. In medicine, it can distort clinical decision-making. A false test result can send a patient into unnecessary treatment, delay the right diagnosis, or undermine confidence in the entire system. The issue is not abstract. It lives in the consequences of believing a machine can deliver certainty without proof.
What whistleblowing changed inside the medical trust chain
Whistleblowers occupy an awkward place in health care and biomedical innovation. They are often framed as obstacles to progress before they are recognized as guards against harm. In the Theranos saga, Shultz’s role represents the kind of internal resistance that becomes essential when a company’s public narrative no longer matches reality. A whistleblower is frequently the first person willing to say what a polished boardroom presentation leaves unsaid.
That willingness is especially important in diagnostics, where failures can remain hidden longer than drug toxicities or procedural complications. A test can look polished on paper and still mislead clinicians if the underlying assay is unreliable. Patients usually never see the technical pathway; they only see the result and act on it. In that setting, faith in the institution matters as much as the machinery.
Shultz’s criticism of the film also reflects a larger professional instinct: medical stories should not be reduced to entertainment when the underlying subject is public harm. The film may be fascinating. The fraud was more than fascinating. It was a warning about how charisma, capital, and media attention can shield bad science from scrutiny for too long.
Why diagnostic fraud leaves a deeper scar than a single company failure
Theranos is often discussed as a business failure, but that framing is incomplete. The deeper injury is to the public’s confidence that laboratory claims will be tested before they are sold. Once that confidence is weakened, every legitimate innovation can face a harder path. Patients become skeptical. Clinicians become cautious. Regulators, investors, and journalists are forced to ask whether the next bold claim is a genuine advance or just another performance.
Holmes’s story also remains potent because it sits at the intersection of medicine and narrative control. She did not merely market a product. She marketed a future. That is why the line between documentary and dramatization matters here. A dramatic film can examine how the deception worked, but it cannot be allowed to replace the historical record or soften the accountability attached to it.
The review’s core assertion is simple: Holmes is still lying. Whether that means she remains attached to a false self-mythology, or whether the culture around her continues to repeat a false version of events, the result is the same. The lie survives when people treat style as evidence.
The medical lesson left behind
A reliable diagnostic system depends on verification, transparency, and the willingness to confront failure early. Theranos violated that logic in a way that still resonates across health care. The company’s rise showed how persuasive a promise can sound when it is wrapped in confidence and secrecy. Its collapse showed what happens when proof is replaced by branding.
Shultz’s response to You Can See Everything is therefore more than a review. It is a reminder that the medical public should resist the urge to romanticize fraud because the story is compelling. Compelling stories can still mislead. In diagnostics, misleading is not a minor literary flaw. It is the difference between evidence and illusion.
What remains unresolved is how many future medical claims will be evaluated first as entertainment and only later as science. That is the risk when a company’s mythology outlives its credibility, and when the audience is invited to admire the performance before it asks whether the test ever worked.